Biblio

Schmalbach CE, Ow TJ, Choi KY, O'Leary M, Lin A, Hughley BB, Emerick KS, Moore B, Lee NY, Zandberg DP et al..  2023.  American Head and Neck Society position statement on the use of PD-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma.. Head Neck. 45(1):32-41.

Groysman M, Gleadhill C, Baker A, Wang SJ, Bearelly S.  2023.  Comparison of margins and survival between transoral robotic surgery (TORS) and non-robotic endoscopic surgery for oropharyngeal cancer.. Am J Otolaryngol. 44(6):103982.

Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim M-O, Ryan WR, Ha PK, Bauman JE et al..  2022.  STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.. Clin Cancer Res. 28(21):4737-4746.

Xu MJue, Plonowska KA, Gurman ZR, Humphrey AK, Ha PK, Wang SJ, El-Sayed IH, Heaton CM, George JR, Yom SS et al..  2020.  Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer.. Laryngoscope. 130(2):E48-E56.

Sun L, Chin R-I, Gastman B, Thorstad W, Yom SS, Reddy CA, Nussenbaum B, Wang SJ, Knackstedt T, Vidimos AT et al..  2019.  Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy.. JAMA Dermatol. 155(4):442-447.

Plonowska KA, Strohl MP, Wang SJ, Ha PK, George JR, Heaton CM, El-Sayed IH, St Clair JMallen-, Ryan WR.  2019.  Human Papillomavirus-Associated Oropharyngeal Cancer: Patterns of Nodal Disease.. Otolaryngol Head Neck Surg. 160(3):502-509.

Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, Yin LX, Ryan WR, Ha PK, Wentz A et al..  2017.  The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.. Cancer. 123(9):1566-1575.